The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization

banner

Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction

08-Feb-2016 | Source : AG-IP News | Visits : 4185
CRANBURY, NJ - Palatin Technologies Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today in a press release that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent Application Serial Number 14/313,258 (the ‘258 application). The allowed claims are for methods of treating female sexual dysfunction using the formulation and dose used in Palatin’s ongoing Phase 3 clinical trials and commercialization upon FDA approval. 
 
Carl Spana, Ph.D., President and CEO of Palatin, commented, “The allowed patent is significant because it applies specifically to methods of treatment of female sexual dysfunction consistent with our projected approved product. Securing strong patent protection is a key component of our development program.”
 
Once issued, the patent is expected to expire no earlier than November 2033, and will further enhance Palatin’s key bremelanotide patent family, which includes U.S. Patent Nos. 6,579,968 and 6,794,489, which expire in June 2020 before patent term extensions. Each of these patents contain composition and method of use claims covering bremelanotide.
 
Top-line results of the Phase 3 trials are on target for release in the third quarter of calendar 2016. Assuming the Phase 3 trials are successful, Palatin will file a New Drug Application in the first half of calendar 2017. 
 
A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The Notice of Allowance for the ‘258 application has been posted on the USPTO public PAIR website. 
 
 
share



Related Articles